Protara Therapeutics, Inc. (TARA)

Key Insights

• The reported transaction was a sale of 1,134 shares of common stock by Jacqueline Zummo, the Chief R&D Officer of Protara Therapeutics, Inc.
• The sale was made pursuant to a Rule 10b5-1 trading plan established by the reporting person, indicating pre-planned insider selling activity.
• Following the reported transaction, the reporting person still beneficially owns 94,827 shares of the company's common stock, maintaining a significant ownership stake.